Metric Snapshot
- Latest value
- $11,899,000
- Coverage range
- 31 Dec 2011 - 31 Mar 2023
- Fact rows
- 54
Shareable Research Card
IVERIC bio, Inc. Share-based Payment Arrangement, Expense
This metric view shows IVERIC bio, Inc. share-based payment arrangement, expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q1 2023
- Latest reported value
- $11,899,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Mar 2023
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q1 2023.
- Latest reported value on this page: $11,899,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
IVERIC bio, Inc.: Share-based Payment Arrangement, Expense
Latest period: Q1 2023. Period end: 31 Mar 2023. Units: USD. Frequency: quarterly and annual.
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
What This Metric Tells You
- Shows the reported level of share-based payment arrangement, expense over 31 Dec 2011 - 31 Mar 2023.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 54 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Share-based Payment Arrangement, Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Meta Platforms, Inc. (["meta"]) | $20,427,000,000 | Year - 31 Dec 2025 | Open Meta Platforms, Inc. Share-based Payment Arrangement, Expense |
| 2 | AMAZON COM INC (["amzn"]) | $19,467,000,000 | Year - 31 Dec 2025 | Open AMAZON COM INC Share-based Payment Arrangement, Expense |
| 3 | MICROSOFT CORP (["msft"]) | $11,974,000,000 | Year - 30 Jun 2025 | Open MICROSOFT CORP Share-based Payment Arrangement, Expense |
| 4 | Alphabet Inc. (["googl", "goog"]) | $9,200,000,000 | Quarter - 31 Dec 2025 | Open Alphabet Inc. Share-based Payment Arrangement, Expense |
| 5 | NVIDIA CORP (["nvda"]) | $6,386,000,000 | Year - 25 Jan 2026 | Open NVIDIA CORP Share-based Payment Arrangement, Expense |
| 6 | BANK OF AMERICA CORP /DE/ (["bac", "bmlpg", "bmlph", "bmlpl", "bacpb", "bacpk", "bacpe", "bmlpj", "bacpl", "bacpm", "bacpn", "bacpo", "bacpp", "bacpq", "bacps", "bacrp", "merpk"]) | $4,200,000,000 | Year - 31 Dec 2025 | Open BANK OF AMERICA CORP /DE/ Share-based Payment Arrangement, Expense |
Metric Details
- Metric
- Share-based Payment Arrangement, Expense (AllocatedShareBasedCompensationExpense)
- Taxonomy
- us-gaap
- Units tracked
- USD
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2011 - 31 Mar 2023
- Facts on this page
- 54
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
IVERIC bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2023 | $33,189,000 | $11,899,000 | +$6,513,000 | +121% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 10 May 2023 | 2023 | Q1 |
| Q4 2022 | $26,676,000 | $8,346,000 | +$4,098,000 | +96% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 01 Mar 2023 | 2022 | FY |
| Q3 2022 | $22,578,000 | $6,556,000 | +$3,930,000 | +150% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 04 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $18,648,000 | $6,388,000 | +$4,309,000 | +207% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 26 Jul 2022 | 2022 | Q2 |
| Q1 2022 | $14,339,000 | $5,386,000 | +$3,094,000 | +135% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 10 May 2023 | 2023 | Q1 |
| Q4 2021 | $11,245,000 | $4,248,000 | +$1,969,000 | +86% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 01 Mar 2023 | 2022 | FY |
| Q3 2021 | $9,276,000 | $2,626,000 | +$779,000 | +42% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 04 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $8,497,000 | $2,079,000 | +$206,000 | +11% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 26 Jul 2022 | 2022 | Q2 |
| Q1 2021 | $8,291,000 | $2,292,000 | -$32,000 | -1.4% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 04 May 2022 | 2022 | Q1 |
| Q4 2020 | $8,323,000 | $2,279,000 | -$98,000 | -4.1% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 01 Mar 2023 | 2022 | FY |
| Q3 2020 | $8,421,000 | $1,847,000 | -$279,000 | -13% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 09 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $8,700,000 | $1,873,000 | -$334,000 | -15% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 04 Aug 2021 | 2021 | Q2 |
| Q1 2020 | $9,034,000 | $2,324,000 | -$146,000 | -5.9% | 01 Jan 2020 | 31 Mar 2020 | 10-Q | 05 May 2021 | 2021 | Q1 |
| Q4 2019 | $9,180,000 | $2,377,000 | -$347,000 | -13% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 24 Feb 2022 | 2021 | FY |
| Q3 2019 | $9,527,000 | $2,126,000 | -$478,000 | -18% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 03 Nov 2020 | 2020 | Q3 |
| Q2 2019 | $10,005,000 | $2,207,000 | -$455,000 | -17% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 06 Aug 2020 | 2020 | Q2 |
| Q1 2019 | $10,460,000 | $2,470,000 | -$612,000 | -20% | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 07 May 2020 | 2020 | Q1 |
| Q4 2018 | $11,072,000 | $2,724,000 | -$984,000 | -27% | 01 Oct 2018 | 31 Dec 2018 | 10-K | 04 Mar 2021 | 2020 | FY |
| Q3 2018 | $12,056,000 | $2,604,000 | -$807,000 | -24% | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 12 Nov 2019 | 2019 | Q3 |
| Q2 2018 | $12,863,000 | $2,662,000 | -$2,326,000 | -47% | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 01 Aug 2019 | 2019 | Q2 |
| Q1 2018 | $15,189,000 | $3,082,000 | -$2,982,000 | -49% | 01 Jan 2018 | 31 Mar 2018 | 10-Q | 08 May 2019 | 2019 | Q1 |
| Q4 2017 | $18,171,000 | $3,708,000 | -$3,063,000 | -45% | 01 Oct 2017 | 31 Dec 2017 | 10-K | 27 Feb 2020 | 2019 | FY |
| Q3 2017 | $21,234,000 | $3,411,000 | -$4,837,000 | -59% | 01 Jul 2017 | 30 Sep 2017 | 10-Q | 02 Nov 2018 | 2018 | Q3 |
| Q2 2017 | $26,071,000 | $4,988,000 | -$3,321,000 | -40% | 01 Apr 2017 | 30 Jun 2017 | 10-Q | 01 Aug 2018 | 2018 | Q2 |
| Q1 2017 | $29,392,000 | $6,064,000 | -$2,268,000 | -27% | 01 Jan 2017 | 31 Mar 2017 | 10-Q | 09 May 2018 | 2018 | Q1 |
| Q4 2016 | $31,660,000 | $6,771,000 | +$485,000 | +7.7% | 01 Oct 2016 | 31 Dec 2016 | 10-K | 28 Feb 2019 | 2018 | FY |
| Q3 2016 | $31,175,000 | $8,248,000 | +$1,207,000 | +17% | 01 Jul 2016 | 30 Sep 2016 | 10-Q | 08 Nov 2017 | 2017 | Q3 |
| Q2 2016 | $29,968,000 | $8,309,000 | +$1,930,000 | +30% | 01 Apr 2016 | 30 Jun 2016 | 10-Q | 02 Aug 2017 | 2017 | Q2 |
| Q1 2016 | $28,038,000 | $8,332,000 | +$3,278,000 | +65% | 01 Jan 2016 | 31 Mar 2016 | 10-Q | 03 May 2017 | 2017 | Q1 |
| Q4 2015 | $24,760,000 | $6,286,000 | +$2,738,000 | +77% | 01 Oct 2015 | 31 Dec 2015 | 10-K | 05 Mar 2018 | 2017 | FY |
| Q3 2015 | $22,022,000 | $7,041,000 | +$3,461,000 | +97% | 01 Jul 2015 | 30 Sep 2015 | 10-Q | 08 Nov 2016 | 2016 | Q3 |
| Q2 2015 | $18,561,000 | $6,379,000 | +$3,196,000 | +100% | 01 Apr 2015 | 30 Jun 2015 | 10-Q | 05 Aug 2016 | 2016 | Q2 |
| Q1 2015 | $15,365,000 | $5,054,000 | +$2,325,000 | +85% | 01 Jan 2015 | 31 Mar 2015 | 10-Q | 09 May 2016 | 2016 | Q1 |
| Q4 2014 | $13,040,000 | $3,548,000 | +$2,284,000 | +181% | 01 Oct 2014 | 31 Dec 2014 | 10-K | 28 Feb 2017 | 2016 | FY |
| Q3 2014 | $10,756,000 | $3,580,000 | +$2,433,000 | +212% | 01 Jul 2014 | 30 Sep 2014 | 10-Q | 05 Nov 2015 | 2015 | Q3 |
| Q2 2014 | $8,323,000 | $3,183,000 | +$2,831,000 | +804% | 01 Apr 2014 | 30 Jun 2014 | 10-Q | 10 Aug 2015 | 2015 | Q2 |
| Q1 2014 | $5,492,000 | $2,729,000 | +$2,621,000 | +2427% | 01 Jan 2014 | 31 Mar 2014 | 10-Q/A | 28 Jul 2015 | 2015 | Q1 |
| Q4 2013 | $2,871,000 | $1,264,000 | 01 Oct 2013 | 31 Dec 2013 | 10-K | 26 Feb 2016 | 2015 | FY | ||
| Q3 2013 | $1,147,000 | +$997,000 | +665% | 01 Jul 2013 | 30 Sep 2013 | 10-Q | 12 Nov 2014 | 2014 | Q3 | |
| Q2 2013 | $352,000 | 01 Apr 2013 | 30 Jun 2013 | 10-Q | 06 Aug 2014 | 2014 | Q2 | |||
| Q1 2013 | $108,000 | 01 Jan 2013 | 31 Mar 2013 | 10-Q | 13 May 2014 | 2014 | Q1 | |||
| Q3 2012 | $150,000 | 01 Jul 2012 | 30 Sep 2012 | 10-Q | 13 Nov 2013 | 2013 | Q3 |
IVERIC bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $26,676,000 | +$15,431,000 | +137% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 01 Mar 2023 | 2022 | FY |
| 2021 | $11,245,000 | +$2,922,000 | +35% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 01 Mar 2023 | 2022 | FY |
| 2020 | $8,323,000 | -$857,000 | -9.3% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 01 Mar 2023 | 2022 | FY |
| 2019 | $9,180,000 | -$1,892,000 | -17% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 24 Feb 2022 | 2021 | FY |
| 2018 | $11,072,000 | -$7,099,000 | -39% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 04 Mar 2021 | 2020 | FY |
| 2017 | $18,171,000 | -$13,489,000 | -43% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 27 Feb 2020 | 2019 | FY |
| 2016 | $31,660,000 | +$6,900,000 | +28% | 01 Jan 2016 | 31 Dec 2016 | 10-K | 28 Feb 2019 | 2018 | FY |
| 2015 | $24,760,000 | +$11,720,000 | +90% | 01 Jan 2015 | 31 Dec 2015 | 10-K | 05 Mar 2018 | 2017 | FY |
| 2014 | $13,040,000 | +$10,169,000 | +354% | 01 Jan 2014 | 31 Dec 2014 | 10-K | 28 Feb 2017 | 2016 | FY |
| 2013 | $2,871,000 | +$2,231,000 | +349% | 01 Jan 2013 | 31 Dec 2013 | 10-K | 26 Feb 2016 | 2015 | FY |
| 2012 | $640,000 | +$392,000 | +158% | 01 Jan 2012 | 31 Dec 2012 | 10-K/A | 28 Jul 2015 | 2014 | FY |
| 2011 | $248,000 | 01 Jan 2011 | 31 Dec 2011 | 10-K | 11 Mar 2014 | 2013 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.